ARTICLE | Company News
Novo Nordisk sales and marketing update
May 11, 2015 7:00 AM UTC
Novo Nordisk launched Novoeight turoctocog alfa in the U.S. to treat hemophilia A. The recommended dosage of the third-generation IV recombinant Factor Vlll ( rFVIII) depends on a patient’s body weig...